Search

Purpose: To evaluate choroidal structure and vasculature in eyes following scleral buckling (SB) for rhegmatogenous retinal detachment (RRD) compared with fellow eyes and control eyes. Methods: This retrospective observational study was performed on 84 eyes: 32 eyes in the study group consisting of patients who had undergone SB due to RRD, 32 fellow eyes of the same patients, and 20 normal control eyes. Choroidal structures and optical coherence tomography angiography (OCTA) parameters were measured and compared among the three study groups. Results: In the study group, the mean total choroidal area (0.6816 ± 0.03188 mm2) was comparable to the fellow eyes (0.7199 ± 0.03056 mm2) and the control group (0.7154 ± 0.17160 mm2). Mean outer luminal area was significantly lower in the study group (0.4089 ± 0.00442 mm2) than in the fellow eyes (0.4437 ± 0.00701 mm2) and the control group (0.4475 ± 0.00442 mm2) (P = 0.042, and 0.047, respectively). The choroidal vascularity index (CVI) and OCTA parameters were not significantly different in eyes with prior SB compared to the fellow eyes and the control group. Conclusion: SB does not significantly affect CVI, choroidal vasculature, and OCTA parameters.

Purpose: To evaluate the safety and efficacy of femtosecond laser-assisted MyoRing implantation with concurrent corneal collagen crosslinking (CXL) compared to MyoRing alone for the treatment of progressive keratoconus. Methods: A total of 60 patients were enrolled in this randomized controlled trial. The patients were randomly allocated into two groups. In the first group, MyoRing was implanted, while in the second, it was inserted in the corneal stroma using the same technique, along with simultaneous CXL. Visual, refractive, topographic, and abberometric outcomes were measured preoperatively and at every postoperative visit. Results: Data of 47 patients were available at the end of the study; 28 in the MyoRing group and 19 in the MyoRing + CXL group. The mean uncorrected distance visual acuity (UDVA) improved from 0.79 ± 0.39 logMAR to 0.52 ± 0.31 logMAR (P < 0.05) in the MyoRing + CXL group and from 0.65 ± 0.38 logMAR to 0.62 ± 0.23 logMAR (P = 0.70) in the MyoRing group. CDVA changed from 0.33 ± 0.19 logMAR to 0.25 ± 0.16 logMAR (P = 0.10) in the MyoRing + CXL group and 0.32 ± 0.22 logMAR to 0.33 ± 0.17 logMAR (P > 0.50) in the MyoRing group. The mean keratometry (Km) decreased from 47.5 ± 2.7 D to 43.8 ± 3.2 D (P < 0.001) in the MyoRing group and 49.3 ± 3.4 D to 45.1 ± 3.0 D (P < 0.001) in the MyoRing + CXL group. Besides, horizontal coma was significantly lower in the MyoRing + CXL group (P = 0.022). Conclusion: MyoRing insertion combined with CXL is a safe and effective method for the treatment of keratoconus. The visual and topographic outcomes were comparable to that for MyoRing insertion after 10 months; however, horizontal coma was significantly lower in the MyoRing + CXL group.